Check out our paper on salvage treatment post BCMA CAR-T Relapse for patients with multiple myeloma! Grateful for the UCSF Myeloma team! Blood Advances Alfred Chung Ajai Chari Nina Shah shagun arora JEFFREY WOLF Sandy Wong Tom Martin Rahul Banerjee, MD, FACP UC San Francisco UCSF Helen Diller Family Comprehensive Cancer Ctr

NEXT SATURDAY! 🗓️ If you're in the Bay Area, join us in person. We will provide parking, lunch, refreshments, and materials to all attendees. Feel free to bring caregivers, family and/or friends. You can register here: buff.ly/3UnYx9I Ajai Chari Alfred Chung

New preprint‼️ While BCMA #CART are amazing for #myeloma, pts with high-risk disease relapse sooner. We show CD70 is a novel CAR target enriched in #HRMM and use structure-guided design to optimize anti-CD70 CAR with enhanced in vivo expansion. Thread👇biorxiv.org/content/10.110…

A shout out 2 the entire #myeloma faculty UCSF Helen Diller Family Comprehensive Cancer Ctr Your presentations were informative & your detailed answers during Q&A were appreciated I forgot to take a picture of entire group, but a captured a few smiling faces. HealthTree Foundation RoundTable #mmsm Ajai Chari Alfred Chung

Just out: International Myeloma Working Group guidelines for bispecific antibodies myeloma. Limited time: Free copy link in the thread. The Lancet Oncology Paula Rodriguez-Otero Jonathan Kaufman, MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Yi Lin Tom Martin marivi mateos Ben Derman Monique Minnema et al thelancet.com/journals/lanon…

Cinco de Myeloma (observed)! ! Love celebrating with my UCSF Helen Diller Family Comprehensive Cancer Ctr family! Sandy Wong Ajai Chari Tom Martin JEFFREY WOLF Alfred Chung

🩸Questions about novel bispecific antibodies for relapsed/refractory multiple myeloma?Join Ajai Chari and Dr. Amrita Krishnan on December 6 in San Diego or livestream for the latest insights.Register now! 👉bit.ly/48kADRs Multiple Myeloma RF #hematology #myeloma #AnswersInCMELive

Ajai Chari Meera Mohan Sundar Shewale Thanks all for the interest. the registry is only of CAR-T toxicities (n=52), of which there were 16 PD, 37 CN palsies, 4 GBS/neuropathy. We are working with centers who contributed cases to determine total denominator. % are not of all pts who had CAR-T

Delayed cart neurotox -likely 4 risk factors demographics, disease burden, high grade crs/icans, peak CAR expansion. However rare so requires continued international collaborations- outstanding work by Dr Kumar and global contributors!

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma | Leukemia nature.com/articles/s4137…

I’ll be at Tandem in Hawaii next week! Im talking about graft-versus-leukemia effects and immunotherapies (plus some bonus CAR T cell data) on Thursday evening. I’m also still looking for postdocs or grad students for my new lab at UCSF so reach out if you’re interested!

A timely and comprehensive review led by Darren Pan on an exciting target with 10 novel therapeutics under investigation summarized in Table 1

#TBT to an unforgettable 29th Annual Winter HEME in Miami Beach! We’re already counting down to our 30th YEAR—returning this February for more insights and the latest in hematologic cancer care. 🌴Save your spot: bit.ly/4kXymAA Dr. Andre Goy Naval Daver, M.D. Ajai Chari

The outstanding Minnie lab at ucsf is looking for postdocs. It’s a great opportunity to work with a talented PI!

Excited about this new story from the lab Blood Journals Portfolio - CD70 is the next big #immunotherapy target in #myeloma! Check out Corynn Kasap's Tweetorial to learn more

Dr. Amrita Krishnan is an amazing mentor, colleague and a leader of the City of Hope Myeloma City of Hope | Orange County program and a national leader. Very pleased she is the SWOG chair and looking forward to the collaboration.